Parenteral Drugs (India) reports standalone net loss of Rs 44.17 crore in the March 2017 quarter

Capital Market June 2, 2017 Last Updated at 16:12 IST

Sales decline 43.81% to Rs 10.31 crore

Net Loss of Parenteral Drugs (India) reported to Rs 44.17 crore in the quarter ended March 2017 as against net loss of Rs 39.27 crore during the previous quarter ended March 2016. Sales declined 43.81% to Rs 10.31 crore in the quarter ended March 2017 as against Rs 18.35 crore during the previous quarter ended March 2016.

For the full year,net loss reported to Rs 113.31 crore in the year ended March 2017 as against net loss of Rs 108.49 crore during the previous year ended March 2016. Sales declined 64.92% to Rs 52.19 crore in the year ended March 2017 as against Rs 148.78 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear EndedMar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var.Sales10.3118.35 -44 52.19148.78 -65 OPM %-191.56-181.53 --61.49-30.58 - PBDT-38.47-50.68 24 -106.03-103.50 -2 PBT-42.71-51.97 18 -125.13-120.56 -4 NP-44.17-39.27 -12 -113.31-108.49 -4

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)